Schrodinger downgraded at Citi after clinical program exit

1 hour ago 1

Citi downgraded Schrodinger (NASDAQ:SDGR) to Neutral from Buy after the AI-focused biotech announced its decision to discontinue a clinical program for a leukemia candidate following the emergence of unexpected adverse events.

Schrodinger (NASDAQ:SDGR), based in New York, announced Thursday it

Read Entire Article

Schrodinger downgraded at Citi after clinical program exit

Related

QuoteMedia reports Q2 results

Industrial production unexpectedly falls in July

SolarMax Technology GAAP EPS of $0.04, revenue of $6.9M

Mill City Ventures III GAAP EPS of $0.11

Next Hydrogen Solutions reports Q2 results

Soleno Therapeutics plunges after short report from Scorpion...

Safe & Green Holdings GAAP EPS of -$4.57, revenue of $0.72M

NextNRG reports Q2 results

Target's outlook is deteriorating on anemic digital traffic,...

Teladoc buys Australian virtual health provider Telecare

AIM ImmunoTech GAAP EPS of -$3.68

Africa Energy reports Q2 results

Conrad GAAP EPS of $1.16

Carbon Streaming Non-GAAP EPS of $0.01

Amplitech Group GAAP EPS of -$0.09 misses by $0.03, revenue ...

Almonty Industries reports Q2 results

Silver Crown Royalties reports Q2 results

Range Impact GAAP EPS of -$0.01, revenue of $1.39M

Intelligent Bio Solutions GAAP EPS of -$2.00, revenue of $3....

Eldorado Gold names former Equinox Gold CEO Milau as new pre...

Trending

Popular

عکس پربازدید از فرزند تازه متولد شده پیمان‌قاسم‌خانی

عکس | ماه کامل بر فراز حرم امام حسین (ع)